Company intelligence / Profile preview

Cadence Pharmaceuticals, Inc.

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Cadence Pharmaceuticals successfully developed and commercialized OFIRMEV (acetaminophen) injection, the first and only intravenous formulation of acetaminophen approved in the U.S. The product received formulary acceptance at over 1,400 U.S. hospitals by October 2011, representing more than 60% of the targeted U.S. IV analgesic market opportunity. By 2013, the company had over 4,000 unique customer accounts, with net product revenue of $23.6 million in Q1 2013.

Therapeutic areas: NeurologyInfectious Diseases
Modalities: Small molecules (intravenous acetaminophen)
Industry: Biotech

Partnerships

Bristol-Myers Squibb Company (referenced clinical development program data)Laboratorios Grifols, S.A. (development, manufacture and supply agreement for OFIRMEV in flexible plastic bags)

Beyond the preview

Go deeper on Cadence Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cadence Pharmaceuticals, Inc..